Document:

<PAGE>

                                                                   EXHIBIT 10.85

                       SENIOR SUBORDINATED LOAN AGREEMENT

THIS SENIOR SUBORDINATED LOAN AGREEMENT (the "AGREEMENT") is entered into as of
the 23rd day of January, 2003, by and among California Beach Restaurants, Inc.,
a California corporation (the "COMPANY") and the party listed on the signature
page hereto (the "LENDER").

         In consideration of the covenants and agreements contained herein, the
Company and the Lender agree as follows:

1.       LOAN.

         1.1      Subject to the terms and conditions contained herein, and in
                  reliance upon the representations, warranties and agreements
                  contained herein, on the date hereof the Lender shall advance
                  amounts (the "LOAN") to the Company in an amount equal to
                  $500,000. The Loan made by the Lender shall be evidenced by a
                  Promissory Note made by the Company to the Lender,
                  substantially in the form of EXHIBIT A (the "NOTE").

         1.2      It is the intent of the parties hereto that the Loan be senior
                  to the rights and claims of the Company's 5% Convertible
                  Subordinated Notes Due October 1, 2003 (the "JUNIOR NOTES").

         1.3      INTEREST. Interest on the Loan shall be payable on the
                  outstanding daily unpaid principal amount until payment in
                  full at the rates set forth herein, to the extent permitted by
                  applicable laws, before and after default, before and after
                  maturity, before and after any judgment and before and after
                  the commencement of any proceeding under any Debtor Relief Law
                  (as hereinafter defined), with interest on overdue interest to
                  bear interest at the Default Rate (as hereinafter defined).
                  Interest shall accrue on the Loan at the rate of fifteen
                  percent (15%) per annum, and shall be due and payable in cash
                  on March 5, 2003. Notwithstanding the foregoing, if any
                  installment of principal or interest under the Note or any
                  other amount payable to the Lender hereunder is not paid when
                  due, or upon and during the continuance of an Event of
                  Default, the outstanding principal amount of the Loan shall
                  bear interest at seventeen percent (17%) per annum (the
                  "DEFAULT RATE") to the extent permitted by applicable law,
                  until paid in full.

         1.4      MATURITY; PREPAYMENT. If not sooner paid, the principal amount
                  of the Loan shall be paid in immediately available funds in
                  cash on March 5, 2003 (the "MATURITY DATE"). The Note may be
                  voluntarily prepaid at any time at the election of the
                  Company; PROVIDED, that (i) any partial prepayment shall be in
                  an amount not less than $25,000 in the aggregate and (ii) each
                  prepayment shall be accompanied by a prepayment of interest
                  accrued to the date of payment on the amount of principal
                  paid. The Company shall provide the Lender a notice setting
                  forth (a) the effective date of such prepayment, (b) the
                  amount of principal to be prepaid, (c) the amount of principal
                  outstanding following such prepayment, and (d) the amount of
                  interest payable with respect to the prepaid principal.

                                       1
<PAGE>

         1.5      COMPUTATIONS; OTHER PAYMENT PROVISIONS. All computations of
                  interest and fees shall be calculated on the basis of a year
                  of 360 days and paid for the actual number of days elapsed. If
                  any payment to be made by the Company shall come due on a day
                  other than a Business Day, payment shall be made on the next
                  succeeding Business Day and the extension of time shall be
                  reflected in computing interest. The amount of each payment
                  hereunder and under the Note shall be made to the Lender in
                  lawful money of the United States, without deduction, offset
                  or counterclaim and in immediately available funds on the day
                  of payment (which much be a Business Day). All payments of
                  principal received after 1:00 p.m., California time, on any
                  Business Day, shall be deemed received on the next succeeding
                  Business Day for purposes of calculating interest thereon. All
                  payments made under this Agreement and the Note shall be made
                  free and clear of, and without reduction by reason of, any
                  tax, assessment or other charge imposed by any governmental
                  entity or authority. The Lender shall keep a record of
                  advances made by it hereunder and payments of principal with
                  respect to the Note, and such record shall be presumptive
                  evidence of the principal amount owing under the Note;
                  PROVIDED, that failure to keep such record shall in no way
                  affect the obligation of the Company to pay all principal
                  amounts advanced hereunder, and interest thereon, as set forth
                  herein.

         1.6      SUBORDINATION. The payment of the principal of, and interest
                  on, the Loan or the Note and any amendments or replacements
                  thereof and any other security interest, lien, claim or right
                  now or hereafter asserted by the Lender with respect to the
                  indebtedness of the Company to the Lender created hereunder,
                  shall be subject, junior and subordinate, in all respects, to
                  the prior payment in full of Senior Debt (as hereinafter
                  defined) of the Company, and to any security interest, lien,
                  claim or right now or hereafter asserted by Senior Debtholders
                  (as hereinafter defined) or their successors and assigns with
                  respect to such Senior Debt or with respect to any collateral
                  therefor. The Lender further agrees that upon the occurrence
                  of a default or event of default (as such terms are defined in
                  the Senior Debt Documents (a "SENIOR DEBT DEFAULT") and
                  without notice of such Senior Debt Default to the Lender, (x)
                  the Senior Debtholders, or their respective successors or
                  assigns, are entitled to be paid all Senior Debt before the
                  Lender is entitled to receive any payments in respect of this
                  Agreement or the Note, (y) the Company may not make any
                  payments to the Lender or with respect to this Agreement or
                  the Note until such payment of all outstanding Senior Debt to
                  the Senior Debtholders has been made in full in cash and (z)
                  for a period not to exceed one hundred eighty (180) days
                  following such Senior Debt Default the Lender may not pursue
                  any enforcement action against the Company. Any payments made
                  to the Lender in violation of this Section 1.7 shall be held
                  in trust for the benefit of the Senior Debtholders (or their
                  respective successors or assigns) and turned over upon the
                  demand of the Senior Debtholders. Notwithstanding the
                  foregoing, in the absence of a Senior Debt Default, the
                  Company shall be permitted to pay interest on and principal of

                                       2
<PAGE>

                  the Loan and the Note in accordance with the terms hereof and
                  thereof. "SENIOR DEBT" shall mean all indebtedness of the
                  Company to (i) Lyon Credit Corporation ("LCC") pursuant to a
                  Promissory Note dated as of April 27, 1999 made by the Company
                  to LCC, a Security Agreement dated as of March 15, 1999 by and
                  between the Company and LCC, and a Security Agreement dated as
                  of April 27, 1999 by and between Sea View Restaurants, Inc.
                  ("SEA VIEW") and LCC, as such documents may be amended,
                  modified, supplemented or restated (the "LCC LOAN DOCUMENTS")
                  and (ii) U.S. Bank National Association ("U. S. BANK" and,
                  together with LCC, the "SENIOR DEBTHOLDERS") pursuant to a
                  Business Loan Agreement dated as of June 22, 2001 by and
                  between the Company and U. S. Bank, a Promissory Note dated as
                  of June 22, 2001 made by the Company to U.S. Bank, a
                  Commercial Security Agreement dated as of June 22, 2001 by and
                  among the Company, U.S. Bank and Sea View and a Commercial
                  Pledge Agreement dated as of June 22, 2001 by and among the
                  Company, U.S. Bank and Sea View, as such documents may be
                  amended, modified, supplemented or restated (the "U.S. BANK
                  LOAN DOCUMENTS" and, together with the LCC Loan Documents, the
                  "SENIOR DEBT DOCUMENTS"), and shall include, but shall not be
                  limited to, all principal, unpaid interest, penalties, costs,
                  fees, premiums and other amounts due Senior Debtholders, or
                  their successors or assigns, pursuant to their respective
                  security loan, security, financing and other agreement,
                  documents or loan instruments and any amendments to or
                  replacements of any of the foregoing. Notwithstanding the
                  foregoing, in the absence of a Senior Debt Default, the
                  Company shall be permitted to pay interest on and principal of
                  the Loan in accordance with their terms. The Senior
                  Debtholders are intended third party beneficiaries of this
                  Section 1.6.

2.       REPRESENTATIONS AND WARRANTIES OF THE COMPANY. The Company represents
         and warrants to the Lender that:

         2.1      ORGANIZATION AND QUALIFICATION. The Company and each of its
                  Subsidiaries (as hereinafter defined) is a corporation duly
                  organized, validly existing and in good standing under the
                  laws of the state of its incorporation and has the requisite
                  corporate power to carry on its business as it is now being
                  conducted, and to own the properties and assets it now owns.
                  The Company and each of its subsidiaries is duly qualified,
                  licensed or domesticated, and in good standing as a foreign
                  corporation authorized to do business in each state or
                  jurisdiction wherein the nature of its activities or its
                  properties owned or leased makes such qualification, licensing
                  or domestication necessary, except where the failure to so
                  qualify, be licensed, domesticated or in good standing would
                  not have a material adverse effect on the Company and its
                  Subsidiaries, considered as a whole. The Company has delivered
                  to the Lender, if it has requested, complete and accurate
                  copies of its Articles of Incorporation and Bylaws and those
                  of each Subsidiary which owns assets constituting in excess of
                  5% of the total assets of the Company and its Subsidiaries on
                  a consolidated basis, together with all amendments thereto.

                                       3
<PAGE>

         2.2      AUTHORIZATION. All corporate action on the part of the
                  Company, its directors and shareholders necessary for the
                  authorization, execution, delivery and performance by the
                  Company of this Agreement and the Note and for the
                  consummation of the transactions contemplated herein and in
                  Exhibit B, and otherwise for the authorization, issuance and
                  delivery of the Note, has been taken and all actions by the
                  board of directors have been unanimous by all members of the
                  board of directors, except for one director who abstained from
                  the vote. This Agreement and the Note upon execution and
                  delivery by the Company, will be valid and binding obligations
                  of the Company, enforceable against the Company in accordance
                  with their terms.

         2.2      ABSENCE OF CERTAIN CHANGES. Since October 31, 2002, the
                  Company and each of its Subsidiaries has conducted its
                  business only in the ordinary course and has not, except as
                  fairly described on SCHEDULE 2.3 hereto, or the Company's Form
                  10-Q for the quarter period ended October 31, 2002 (the
                  "Company's 10-Q"), or pursuant to this Agreement:

                  (a)      suffered any material adverse change in its
                           operations, properties or financial condition or
                           prospects;

                  (b)      incurred any increase in indebtedness for borrowed
                           money over the level thereof reflected on its audited
                           consolidated balance sheet as of April 30, 2002 (the
                           "COMPANY BALANCE SHEET"), except for borrowings made
                           in the ordinary course of business;

                  (c)      discharged or paid any obligation or liability
                           material to it, other than current liabilities shown
                           on the Company Balance Sheet and current liabilities
                           incurred since the date of the Company Balance Sheet
                           discharged or paid in the ordinary course of business
                           or consistent with past practice;

                  (d)      permitted any of its assets to be subject to any
                           material security interest, restriction or charge of
                           any kind other than purchase money security
                           interests;

                  (e)      received any notice of termination of, or default
                           under, any contract, lease or other agreement, or
                           suffered any material damage, destruction or loss
                           (whether or not covered by insurance);

                  (f)      issued or sold any of its securities, or issued or
                           sold any options, rights or warrants with respect
                           thereto, or acquired any capital stock or other
                           securities of any corporation or any interest in any
                           business enterprise, or otherwise made any loan or
                           advance to or investment in any person, firm or
                           corporation, except for normal business advances to
                           employees consistent with past practice;

                  (g)      written off as uncollectible any accounts receivable,
                           except for write-offs in the ordinary course of
                           business or consistent with past practice, or in any
                           event in excess of an aggregate of $25,000;

                                       4
<PAGE>

                  (h)      canceled or compromised any debts or waived or
                           permitted to lapse any claims or rights of
                           substantial value, or sold, leased, transferred or
                           otherwise disposed of any of its properties or assets
                           (real, personal or mixed, tangible or intangible)
                           except in the ordinary course of business or
                           consistent with past practice;

                  (i)      granted any general increase in the compensation of
                           officers or employees (including any such increase
                           pursuant to any bonus, pension, profit sharing or
                           other plan or commitment) or any increase in the
                           compensation payable or to become payable to any
                           officer or employee, except for increases in the
                           ordinary course of business or consistent with past
                           practice;

                  (j)      made any material capital expenditure or commitment
                           for any addition to property, plant or equipment not
                           in the ordinary course of business, or in any event
                           in excess of an aggregate of $50,000;

                  (k)      declared, paid or set aside for payment any dividend
                           or other distribution in respect of its capital
                           stock, or directly or indirectly, redeemed, purchased
                           or otherwise acquired any shares of its capital stock
                           or other securities of the Company or any of its
                           Subsidiaries;

                  (l)      paid, loaned or advanced any amount to, or sold,
                           transferred or leased any properties or assets to, or
                           entered into any agreement or arrangement with, any
                           of its officers, directors or "affiliates," as such
                           term is defined in the rules and regulations of the
                           Securities and Exchange Commission (the "SEC"),
                           except for normal business advances to employees
                           consistent with past practice, directors' fees,
                           compensation to officers and compensation increases
                           permitted by clause (i) of this Section 2.3;

                  (m)      settled any claim, action or proceeding pending or
                           threatened against or relating to the Company or any
                           of its Subsidiaries before any court or governmental
                           or regulatory authority or body for an amount in
                           excess of an aggregate of $25,000; or

                  (n)      agreed, whether in writing or otherwise, to take any
                           action described in this Section 2.3.

                                       5
<PAGE>

         2.3      FINANCIAL STATEMENTS AND REPORTS.

                  (a)      The Company has timely filed all required forms,
                           reports, statements and documents with the SEC, all
                           of which have complied in all material respects with
                           all applicable requirements of the Securities Act of
                           1933, as amended (the "SECURITIES ACT"), and the
                           Securities Exchange Act of 1934 (the "EXCHANGE ACT").
                           The Company has delivered to the Lender true and
                           complete copies of the Company's (i) Annual Report on
                           Form 10-K for the fiscal years ended April 30, 2000,
                           2001 and 2002, (ii) Proxy Statements relating to all
                           meetings of the Company's shareholders (whether
                           annual or special) held since April 30, 2000, (iii)
                           all other forms, reports, statements and documents
                           filed by the Company with the SEC since April 30,
                           2000, and (iv) all reports, statements, documents and
                           other information provided by the Company to public
                           security holders since April 30, 2000 (collectively,
                           the items referred to in clauses (i) through (iv) are
                           hereinafter referred to as the "COMPANY Reports"). As
                           of their respective dates, the Company Reports did
                           not contain any untrue statement of a material fact
                           or omit to state a material fact required to be
                           stated therein or necessary to make the statements
                           therein, in light of the circumstances under which
                           they were made, not misleading. The financial
                           statements of the Company and its Subsidiaries
                           included or incorporated by reference in the Company
                           Reports were prepared in accordance with generally
                           accepted accounting principles applied on a
                           consistent basis and present fairly the financial
                           position, results of operations and changes in
                           financial position of the Company and its
                           Subsidiaries as of the dates and for the periods
                           indicated, except that the unaudited interim
                           financial statements may not contain all of the
                           footnotes required by generally accepted accounting
                           principles and may be subject to year-end adjustment.

                  (b)      The Company has delivered to the Lender true and
                           complete copies of the Company's balance sheet as of
                           October 31, 2002 (the "INTERIM BALANCE Sheet"). The
                           Interim Balance Sheet was prepared in accordance with
                           (i) generally accepted accounting principles applied
                           on a consistent basis and (ii) the rules and
                           requirements of the SEC. The Interim Balance Sheet
                           presents fairly the consolidated financial position
                           of the Company and its Subsidiaries as of July 31,
                           2002. The total assets of the Company, as set forth
                           on the Interim Balance Sheet, equals or exceeds
                           $2,000,000. The Lender agrees to keep the Interim
                           Balance Sheet confidential.

                                       6
<PAGE>

         2.4      NO UNDISCLOSED LIABILITIES. Except as and to the extent
                  reflected on the Company Balance Sheet and the footnotes
                  thereto, as of October 31, 2002, neither the Company nor any
                  of its Subsidiaries had any liabilities or obligations
                  (absolute, accrued, contingent or otherwise) material to the
                  Company and its Subsidiaries taken as a whole of a nature
                  required by generally accepted accounting principles to be
                  reflected on a consolidated balance sheet of the Company and
                  its Subsidiaries ("LIABILITIES"). Since October 31, 2002,
                  neither the Company nor any of its Subsidiaries has incurred
                  any Liabilities material to the Company and its Subsidiaries
                  taken as a whole, except Liabilities incurred in the ordinary
                  course of business.

         2.5      CONSENTS AND APPROVALS.

                  (a)      No notice to or filing with, and no authorization,
                           consent or approval of, any domestic or foreign court
                           or any public or governmental body or authority is
                           necessary for the execution and delivery of this
                           Agreement and the Note by the Company and the
                           performance of its obligations hereunder, except for
                           notices or filings the failure to give or make, and
                           authorizations, consents and approvals the failure to
                           obtain, would not, individually or in the aggregate,
                           have a material adverse effect on the financial
                           condition, business or results of operations of the
                           Company and its Subsidiaries taken as a whole or
                           adversely affect the ability of the Company perform
                           its obligations under this Agreement or the Note (a
                           "MATERIAL ADVERSE EFFECT").

                  (b)      No authorization, consent or approval of any person
                           or entity is necessary for the execution and delivery
                           by the Company of this Agreement and the Note, and
                           the performance of its obligations hereunder, other
                           than (i) pursuant to Section 2.6(a) and (ii) the
                           consent of U.S. Bank, which has either been obtained
                           by the Company or which the Company will use its best
                           efforts to obtain.

                  (c)      Upon execution and delivery of a Junior Note Consent
                           by the holder thereof, such Junior Note will be
                           subordinated to, and junior in the right of payment
                           of, the Loan and the Note. True and correct copies of
                           the Junior Note Consents will be provided to the
                           Lender promptly (but in any case within 5 Business
                           Days) after execution and delivery thereof by the
                           parties thereto.

                                       7
<PAGE>

         2.6      NO VIOLATIONS. Except as set forth on SCHEDULE 2.7 hereto, the
                  execution and delivery of this Agreement does not, and the
                  documents and agreements required to be executed in connection
                  herewith and the performance by the Company and its
                  Subsidiaries of their obligations hereunder and the
                  consummation of the transactions contemplated hereby will not,
                  violate, conflict with or result in a breach of any provision
                  of, or constitute a default (or an event which, with notice or
                  lapse of time or both, would constitute a default) under, or
                  result in the termination of, or accelerate the performance
                  required by, or result in a right of termination or
                  acceleration under, or result in the creation of any lien,
                  security interest, charge or encumbrance upon any of the
                  properties or assets of the Company or any of the Subsidiaries
                  under any of the terms, conditions or provisions of (i) the
                  respective charters or bylaws of the Company or the
                  Subsidiaries, (ii) subject to compliance with the statutes and
                  regulations referred to in Section 2.6 above, any statute,
                  law, ordinance, rule, regulation, judgment, decree, order,
                  injunction or writ applicable to the Company or any of the
                  Subsidiaries or any properties or assets of the Company or any
                  of the Subsidiaries, or (iii) any note, bond, mortgage,
                  indenture, license, franchise, permit, concession, contract,
                  agreement, lease or other instrument or agreement of any kind
                  to which the Company or any of the Subsidiaries is now a party
                  or by which the Company or any of the Subsidiaries or any of
                  their respective properties or assets may be bound, excluding
                  from the foregoing clauses (ii) and (iii) violations,
                  conflicts, breaches, defaults, terminations, accelerations or
                  creations of liens, security interests, charges or
                  encumbrances which would not, individually or in the
                  aggregate, have a Material Adverse Effect. The businesses of
                  the Company and its Subsidiaries are not being conducted in
                  violation of any law, ordinance or regulation of any
                  governmental entity ("VIOLATIONS"), except for Violations
                  which either individually or in the aggregate will not have a
                  Material Adverse Effect. Set forth on SCHEDULE 2.7 hereto is a
                  list of all Violations of which the Company has knowledge
                  which could, individually or in the aggregate, have a Material
                  Adverse Effect.

         2.7      LITIGATION, ETC. Except as described on SCHEDULE 2.8 hereto,
                  there is no claim, action or proceeding pending or, to the
                  best knowledge of the Company, threatened against or relating
                  to the Company or any of its Subsidiaries before any court or
                  governmental or regulatory authority or body acting in an
                  adjudicative capacity which individually or in the aggregate,
                  if adversely determined, would have a Material Adverse Effect.
                  Neither the Company nor any of its Subsidiaries is subject to
                  any outstanding order, writ, injunction or decree which
                  individually or in the aggregate could have a Material Adverse
                  Effect.

                                       8
<PAGE>

         2.8      LEASE/CONCESSION AGREEMENTS. All leases and concession
                  agreements pursuant to which the Company and each of its
                  Subsidiaries leases real property and improvements material to
                  the conduct of its business and operations (collectively, the
                  "LEASES") are in full force and effect and constitute legal,
                  valid and binding obligations of the parties thereto,
                  enforceable in accordance with their respective terms, except
                  as the same may be limited by bankruptcy, insolvency,
                  reorganization, moratorium or similar laws now or hereafter in
                  effect relating to or limiting creditors' rights or by legal
                  principles of general applicability governing the availability
                  of equitable remedies. Neither the Company nor any of its
                  Subsidiaries has assigned its rights and interests under the
                  Leases. Except as set forth in the Company's 10-Q, nothing has
                  come to the attention of the Company which (whether with or
                  without notice, lapse of time or both) would constitute a
                  material breach or default by any party under the Leases.

         2.9      TAXES. All tax returns required to be filed by the Company and
                  its Subsidiaries have been duly and timely filed, and all
                  taxes, interest, penalties, assessments and/or deficiencies
                  shown to be due on such tax returns or for which the Company
                  has received tax notices have in all respects been paid or
                  adequate provision for the payment thereof has been made. The
                  Company and its Subsidiaries have no material tax deficiency
                  or claim outstanding, assessed or, to the best of knowledge of
                  the Company, proposed against the Company and its
                  Subsidiaries.

         2.10     LICENSES, PERMITS AND AUTHORIZATIONS. The Company and its
                  Subsidiaries have all approvals, licenses or other permits of
                  all governmental or regulatory agencies, whether federal,
                  state or local, the absence of which would materially impair
                  the operations of their businesses taken as a whole as they
                  are presently being conducted. Set forth on SCHEDULE 2.11
                  hereto is a list of all California Department of Alcoholic
                  Beverage Control licenses and permits issued to the Company
                  and its Subsidiaries and in effect on the date hereof or which
                  will be in effect on the Closing Date.

3.       COVENANTS OF THE COMPANY. The Company hereby covenants and agrees as
         follows:

                                       9
<PAGE>

         3.1      ANNUAL AND QUARTERLY FINANCIAL INFORMATION. The Company will
                  furnish the following reports to the Lender for so long as the
                  Loan is outstanding pursuant to this Agreement:

                  (a)      As soon as practicable after the end of each fiscal
                           year, and in any event within 120 days after the end
                           of each fiscal year, consolidated balance sheets of
                           the Company and its Subsidiaries, as of the end of
                           such fiscal year, and consolidated statements of
                           income and consolidated statements of changes in
                           financial position of the Company and its
                           Subsidiaries for such year, prepared in accordance
                           with generally accepted accounting principles and
                           setting forth in each case in comparative form the
                           figures for the previous fiscal year, all in
                           reasonable detail and certified by independent public
                           accountants of reputable standing selected by the
                           Company. Notwithstanding the foregoing, at any time
                           the Company is required to file reports pursuant to
                           the Exchange Act, the obligation contained in this
                           clause (a) shall be satisfied by delivery of a copy
                           of the Company's annual report on Form 10-K for each
                           fiscal year within fifteen Business Days of filing
                           thereof with the SEC.

                  (b)      As soon as practicable after the end of the first,
                           second and third quarterly accounting periods in each
                           fiscal year of the Company, and in any event within
                           45 days thereafter, a consolidated balance sheet of
                           the Company and its Subsidiaries as of the end of
                           each such quarterly period, and consolidated
                           statements of income and consolidated cash flow
                           statements of the Company and its Subsidiaries for
                           such period and for the current fiscal year to date,
                           prepared in accordance with generally accepted
                           accounting principles (subject to normal audit
                           adjustment and except that no supporting statements,
                           schedules, footnotes or other such disclosure
                           required by generally accepted accounting principles
                           need be included), all in reasonable detail and
                           signed, subject to changes resulting from year-end
                           audit adjustments, by the Chief Financial Officer of
                           the Company. Notwithstanding the foregoing, at any
                           time the Company is required to file reports pursuant
                           to the Exchange Act, the obligation contained in this
                           clause (b) shall be satisfied by delivery of a copy
                           of the Company's quarterly report on Form 10-Q for
                           each quarterly accounting period within fifteen
                           Business Days of filing thereof with the SEC.

                  (c)      The Company will furnish to the Lender promptly (but
                           in any event within fifteen Business Days) after the
                           mailing to its stockholders generally of each annual
                           report, proxy statement or other report or
                           communication, a copy of each such report, proxy
                           statement or other report or communication and
                           promptly (but in any event within fifteen business
                           days) after any filing by the Company with the SEC or
                           any governmental agency or agencies substituted for
                           such commission, or with any national securities
                           exchanges of any annual or periodic or special report
                           or registration statement, a copy of such report or
                           statement and copies of all press releases and other
                           statements made available generally by the Company to
                           the public concerning material developments in the
                           Company's business.

                                       10
<PAGE>

         3.2      REIMBURSEMENT OF EXPENSES. The Company shall pay all expenses
                  of the Lender included in connection with this Agreement, the
                  Note and the enforcement thereof, including the reasonable
                  fees and expenses of counsel.

         3.3      LIMITATION ON INDEBTEDNESS. The Company will not incur
                  Indebtedness without the prior written consent of the Lender,
                  other than Indebtedness to the Senior Debtholders in
                  accordance with the terms of the Senior Debt Documents.
                  "INDEBTEDNESS" shall mean obligations for money borrowed,
                  obligations evidenced by bonds, debentures, notes or other
                  similar instruments, reimbursement obligations with respect to
                  letters of credit, bankers' acceptances or similar facilities,
                  the purchase price of property or services (excluding trade
                  accounts payable or accrued liabilities arising in the
                  ordinary course of business which are not overdue or which are
                  being contested in good faith), obligations under capitalized
                  leases, and guarantees and other similar obligations.

         3.4      SUBSEQUENT TRANSACTION. The Company agrees to use its
                  reasonable commercial efforts to effectuate the transactions
                  set forth in the Term Sheet attached hereto as Exhibit B on or
                  prior to February 21, 2003.

4.       EVENTS OF DEFAULT; REMEDIES.

         4.1      DEFAULTS AND REMEDIES. The occurrence of any one or more of
                  the following shall constitute an event of default hereunder
                  ("EVENT OF DEFAULT"), whatever the reason therefor:

                  (a)      the Company fails to pay any installment of principal
                           on any of the Notes on the date when due;

                  (b)      the Company fails to pay any installment of interest
                           on any of the Notes within (30) days after the date
                           when due;

                  (c)      the Company fails to perform, observe or comply with
                           any term, covenant or agreement contained in this
                           Agreement or the Note;

                  (d)      any representation or warranty in this Agreement or
                           any document delivered by the Company pursuant to
                           this Agreement, shall fail to be true and correct in
                           all material respects; or

                  (e)      proceedings for relief under any bankruptcy law or
                           any law for the relief of debtors ("DEBTOR RELIEF
                           LAW") shall be instituted by or against the Company,
                           or any order, judgment or dissolution or division;
                           PROVIDED, HOWEVER, with respect to an involuntary
                           petition in bankruptcy, such petition shall not have
                           been dismissed within sixty (60) days after the
                           filing of such petition;

                                       11
<PAGE>

then, and in any such event, so long as the same may be continuing, the Lender
may, by notice in writing to the Company declare all amounts owing with respect
to this Agreement or the Note to be, and it shall thereupon forthwith become,
immediately due and payable without presentment, demand, protest or other notice
of any kind, all of which are hereby expressly waived by the Company; PROVIDED
that in the event of any Event of Default specified in Section 5.1(e) all such
amounts shall become immediately due and payable automatically and without any
requirement of notice from the Lender.

         4.2      REMEDIES. Upon the occurrence and continuance of any Event of
                  Default, the Lender may proceed to protect, exercise, and
                  enforce its respective rights and remedies under this
                  Agreement and the Note and all rights available at law or in
                  equity.

         4.3      WAIVER OF DEFAULT. Any Event of Default waived in accordance
                  with Section 6.1 shall be deemed to have been cured and not to
                  be continuing; but no such waiver shall be deemed a continuing
                  waiver or shall extend to or affect any subsequent like
                  default or impair any rights arising therefrom.

5.       MISCELLANEOUS.

         5.1      AMENDMENT; WAIVERS. Any consent or approval required or
                  permitted by this Agreement to be given by the Lender may be
                  given, and any term of this Agreement may be amended, and the
                  performance or observance by the Company of any terms of this
                  Loan Agreement, or the continuance of any Event of Default may
                  be waived (either generally or in a particular instance and
                  either retroactively or prospectively) with, but only with,
                  the written consent of the Company and the Lender.
                  Notwithstanding the foregoing, no amendment, modification or
                  waiver shall, without the written consent of the Lender (i)
                  reduce or forgive the principal amount of the Loan, or reduce
                  the rate or rates of interest on the Note; (ii) postpone or
                  extend the Maturity Date or any other regularly scheduled
                  dates for payments of principal of, or interest on, the Loan,
                  or modify any of the provisions relating to amounts, timing or
                  application of payments or prepayments of the Loan (it being
                  understood that any vote to rescind any acceleration made
                  pursuant to Section 4.1 of amounts owing with respect to the
                  Loan shall require the approval of the Lender); (iii) amend or
                  waive any provision relating to the subordination of the
                  claims of the holders of the Junior Notes or any other
                  obligations subordinated to the Note; or (iv) amend or modify
                  the terms of the subordination of the Note to the claims of
                  the Senior Debtholders or agree to subordinate the Note to any
                  other obligations of the Company.

         5.2      SURVIVAL OF REPRESENTATIONS AND WARRANTIES. Except as provided
                  hereinafter, all of the warranties and representations made by
                  the Company and the Lender in this Agreement or any document,
                  certificate, schedule or instrument delivered in connection
                  herewith shall survive the Closing and shall continue in
                  effect, notwithstanding any investigation by or on behalf of
                  the Lender.

                                       12
<PAGE>

         5.3      ENTIRE AGREEMENT; ASSIGNMENT. This Agreement and the Note (a)
                  constitute the entire agreement between the parties with
                  respect to the subject matter hereof and supersede all other
                  prior agreements and understandings, both written and oral,
                  among the parties or any of them with respect to the subject
                  matter hereof and (b) may be assigned, in whole or in part, by
                  the Lender or by operation of law.

         5.4      ENFORCEMENT OF THE AGREEMENT. The parties hereto agree that
                  irreparable damage would occur in the event that any of the
                  provisions of this Agreement were not performed in accordance
                  with their specific terms or were otherwise breached. It is
                  accordingly agreed that the parties shall be entitled to an
                  injunction or injunctions to prevent breaches of this
                  Agreement and to enforce specifically the terms and provisions
                  hereof in any federal or state court located in the State of
                  California (as to which the parties agree to submit to
                  jurisdiction for the purposes of such action), this being in
                  addition to any other remedy to which they are entitled at law
                  or in equity.

         5.5      FURTHER ASSURANCES. The Company shall, at its expense and
                  without expense to the Lender, do, execute and deliver such
                  further acts and documents as the Lender may from time to time
                  reasonably request for the assurance and confirming unto the
                  Lender the rights hereby created or intended now or hereafter
                  so to be, or for carrying out the intention or facilitating
                  the performance of the terms of this Agreement and the Note.

         5.6      VALIDITY. The invalidity or unenforceability of any provision
                  of this Agreement shall not affect the validity or
                  enforceability of any other provisions of this Agreement,
                  which shall remain in full force and effect.

         5.7      NOTICES. All notices, requests, claims, demands and other
                  communications hereunder shall be in writing and shall be
                  deemed to have been duly given when delivered, if delivered in
                  person, when confirmation is received, if sent by telecopier,
                  on the next Business Day, if accepted for overnight delivery
                  by a nationally-known courier guaranteeing overnight delivery
                  service (charges prepaid), or three Business Days after being
                  deposited in the U.S. mail if sent by registered or certified
                  mail (postage prepaid, return receipt requested) to the
                  respective parties at the address or telecopier number set
                  forth opposite each such party's name on the signature page or
                  to such other address as the person to whom notice is given
                  may have previously furnished to the others in writing in the
                  manner set forth above.

         5.8      GOVERNING LAW. This Agreement shall be governed by and
                  construed in accordance with the laws of the State of
                  California regardless of the laws that might otherwise govern
                  under principles of conflicts of laws applicable thereto.

                                       13
<PAGE>

         5.9      DESCRIPTIVE HEADINGS. The descriptive headings herein are
                  inserted for convenience of reference only and are not
                  interpreted to be a part of or to affect the meaning or
                  interpretation of this Agreement.

         5.10     PARTIES IN INTEREST. This Agreement shall be binding upon and
                  inure solely to the benefit of each party hereto, and except
                  as expressly set forth in Section 1.6, nothing in this
                  Agreement, express or implied, is intended to confer upon any
                  other person any rights or remedies of any nature whatsoever
                  under or by reason of this Agreement.

         5.11     COUNTERPARTS. This Agreement may be executed in counterparts,
                  each of which shall be deemed to be an original, but all of
                  which shall constitute one and the same agreement.

                                       14
<PAGE>

                  IN WITNESS WHEREOF, the parties have caused this Agreement to
be duly executed and delivered as of the day and year first above written.

                                      CALIFORNIA BEACH RESTAURANTS, INC.

                                      By: /S/ Richard Powell
                                          ------------------------------
                                              Richard Powell
                                              President

                                      17383 Sunset Boulevard, Suite 140
                                      Pacific Palisades, CA  90272
                                      Attention:  President
                           Address:   Telecopier Number: (310) 459-9356

                                      THE LENDER:

                                      RLH SURF, a California General Partnership

                                      By: /S/ J. Christopher Lewis
                                         --------------------------------
                                              J. Christopher Lewis
                                              General Partner

                                      RLH Surf
                                      300 S. Grand Avenue, 29th Floor
                                      Los Angeles, California  90071
                                      Attention:  J. Christopher Lewis
Address for Notices:                  Telecopier Number: (213) 229-8597

                                       15<PAGE>

EXHIBIT 10.12
                              RESTRUCTURE AGREEMENT

         THIS RESTRUCTURE AGREEMENT (the "Agreement") is entered into on March
21, 2003 (the "Effective Date"), by and among Triton Private Equities Fund, L.P.
("Triton"), Nurescell Inc. ("Nurescell"), Advanced Technology Industries, Inc.
("ATI") and ATI Nuklear AG ("ATI Sub"), with reference to the following facts
and circumstances:

         A. Nurescell and ATI Sub have previously entered into a "License
Agreement" dated as of August 15, 2000 (the "License Agreement"), an "Investment
Agreement" dated as of August 17, 2000 (the "Investment Agreement") and a
Modification Agreement dated as of June 11, 2001 (the "Modification Agreement"),
each of which was amended by a "Transaction Restructure Agreement" entered into
as of September 30, 2001 by Nurescell, ATI and ATI Sub (the "2001 Restructure
Agreement"). Under the License Agreement, as amended, Nurescell has licensed to
ATI Sub certain "Technology" (as described in Exhibit 1 to the License
Agreement) in return for specified royalty payments.

         B. Nurescell presently owes ATI (i) approximately $176,158 for
short-term cash advances previously made by ATI to Nurescell and (ii) various
sums for legal fees that ATI has paid on Nurescell's behalf. Nurescell is also
indebted to ATI Sub pursuant to a $1 million promissory note (the "ATI Sub
Note"). The ATI Sub Note is secured by (i) 15,000,000 unissued shares of
Nurescell's common stock ("Nurescell Common Stock"), (ii) a first priority
security interest in the Technology and (iii) all royalties due to Nurescell
pursuant to Section 4.3 of the License Agreement (collectively, the
"Collateral"). Nurescell is presently in default with respect to its obligations
to ATI and its obligations to ATI Sub under the ATI Sub Note.

         C. Nurescell is indebted to Triton (collectively, the "Nurescell Debt")
pursuant to (i) Nurescell's Series 1999-A 8% Convertible Promissory Note dated
December 15, 1999, which came due as to $335,000 in principal on December 1,
2001 (the "1999 Note"), (ii) Nurescell's Series 2000-A 8% Convertible Promissory
Note dated February 8, 2000, which came due as to $385,000 in principal on
December 1, 2001 (the "2000 Note"), (iii) accrued interest on the 1999 Note and
2000 Note (taking into account Triton's prior conversion of $50,000 of the 1999
Note) and (iv) accrued penalties due to Nurescell's failure to register the
shares underlying the 1999 and 2000 Notes as required by the Registration Rights
Agreements (the "Registration Agreements") between Triton and Nurescell dated
December 15, 1999 and February 8, 2000 (again taking into account Triton's prior
conversion of $50,000 of the 1999 Note). Nurescell is presently in default with
respect to its obligations to Triton in connection with the Nurescell Debt.

<PAGE>

         D. In light of the fact that Nurescell is unable to satisfy its
obligations to ATI, ATI Sub and Triton, the parties desire to restructure their
relationship so that (i) through conversion into Nurescell Common Stock of at
least a portion of the Nurescell Debt, Triton is able to become the majority
shareholder of Nurescell and control its operations, (ii) Nurescell's Articles
of Incorporation are amended to increase the number of authorized shares so
that, if Triton so desires, Triton is able to convert all of the Nurescell Debt
into Nurescell Common Stock (assuming a conversion price of $0.001 per share)
and (iii) ATI and/or ATI Sub are able to acquire the Technology in return for
(A) cancellation of the ATI Sub Note, the 2001 Restructure Agreement, the
Investment Agreement, the License Agreement, the Modification Agreement and all
other obligations of Nurescell to ATI or ATI Sub (collectively, the "ATI
Obligations") and (B) release of the Collateral for the ATI Sub Note, in each
case on the terms and conditions set forth herein.

         NOW, THEREFORE, in consideration of the representations, warranties and
agreements herein contained, the receipt and sufficiency of which are hereby
acknowledged, the parties hereto agree as follows:

                                    ARTICLE I
                CONVERSION OF NURESCELL DEBT AND RELATED MATTERS

         1.01 INITIAL TRITON CONVERSION. Immediately after (i) Nurescell's
current Board of Directors adopts resolutions in substantially the form of the
attached Exhibit "A" and (ii) all current directors and officers subsequently
resign from their positions with Nurescell (such resignations being in the form
of the attached Exhibit "B"), Triton shall convert into Nurescell Common Stock
at least that much of the Nurescell Debt as would give Triton a majority of the
then-outstanding shares of Nurescell Common Stock (which is anticipated to
require a conversion for at least 16,070,239 shares). To the extent requested by
Triton, Nurescell shall use its best efforts to assist Triton with the foregoing
conversion (the "Initial Conversion"), including appropriate instructions to
Nurescell's stock transfer agent.

         1.02 INCREASE IN AUTHORIZED SHARES. Upon completion of the Initial
Conversion, Nurescell and Triton shall each use their best efforts to (i) amend
Nurescell's Articles of Incorporation to increase the number of authorized
shares (the "Share Increase") to an amount that will at least allow the balance
of the Nurescell Debt to be converted into Nurescell Common Stock (assuming a
conversion price of $0.001 per share) and (ii) prepare, file with the Securities
and Exchange Commission and deliver to Nurescell's shareholders an Information
Statement (the "Information Statement") describing both the Share Increase and
the transfer of the Technology pursuant to this Agreement (the "Technology
Transfer") in the manner required by law. The parties acknowledge and agree that
the Share Increase and the Technology Transfer will become effective 20 days
after the Information Statement has been sent or given to Nurescell's
shareholders. To the extent reasonably requested by Nurescell and/or Triton,
ATI, in its capacity as a Nurescell shareholder, shall cooperate in causing the
Share Increase to become effective.

         1.03 SUBSEQUENT TRITON CONVERSIONS. After the Effective Date, Triton
may from time-to-time, in its sole discretion, cause some or all of the
remaining Nurescell Debt to be converted into common stock. To the extent
requested by Triton, Nurescell shall use its best efforts to assist Triton with
each such conversion including, but not limited to, providing confirmation of
the prior approval of such conversion by Nurescell's Board of Directors and
appropriate instructions to Nurescell's stock transfer agent.

<PAGE>

                                   ARTICLE II
                 TRANSFER OF THE TECHNOLOGY AND RELATED MATTERS
                 ----------------------------------------------

         2.01     TECHNOLOGY TRANSFER AND OTHER TRANSACTIONS.

                  (a) On the Closing Date (as defined below), the following
shall automatically occur without any further action of the parties:

                  (i) as of the Closing Date, Nurescell, ATI and ATI Sub shall
be deemed to have entered into an agreement in the form of the attached Exhibit
"C" (the "Assignment Agreement"), the terms of which shall be incorporated into
this Agreement as of the Closing Date if set forth here in full, pursuant to
which the Technology shall be transferred to ATI Sub in "as is" condition;

                  (ii) as of the Closing Date, the parties hereto shall be
deemed to have entered into an agreement in the form of the attached Exhibit "D"
(the "Mutual Release"), the terms of which shall be incorporated into this
Agreement as of the Closing Date as if set forth here in full;

                  (iii) as of the Closing Date, the Collateral for the ATI Sub
Note shall be deemed forever released and neither ATI nor ATI Sub shall have any
further rights with respect thereto (except as provided in clause (i) above);
and

                  (iv) as of the Closing Date, the ATI Obligations shall be
cancelled and of no further force and effect.

                  (b) The parties agree that for all purposes the "Closing Date"
shall be the 23rd day (or if such day is a Saturday, Sunday or holiday, the next
business day thereafter) following the date that the Information Statement has
been sent or given to Nurescell's shareholders; provided, however, that if at
least three (3) days prior to the Closing Date either Triton or ATI shall give
the other a dated written notice (the "Notice") which (i) states that one or
more specified conditions listed in Section 2.02 below (the "Transfer
Conditions") has not been satisfied or waived and (ii) provides the basis for
such statement in reasonable detail, then the Closing Date shall be delayed
until the specified Transfer Condition(s) has been satisfied or waived. In the
event that a Notice is given, the parties shall thereafter reasonably cooperate
to promptly satisfy the Transfer Condition(s) specified therein and the Closing
Date shall be the date upon which the party giving the Notice acknowledges in
writing that the specified Transfer Condition(s) has now been satisfied or
waived (which acknowledgment shall not be unreasonably withheld or delayed);
provided, however, that if such satisfaction or waiver does not occur within
twenty (20) days after the date of the Notice, the party giving the Notice shall
thereafter have the right, in its sole discretion, to terminate this Agreement
if permitted under Section 5.01(b) below.

         2.02 CONDITIONS TO TRANSFER AND OTHER TRANSACTIONS. The Transfer
Conditions shall consist of all of the following:

                  (a) the Initial Conversion shall have occurred;

<PAGE>

                  (b) the Share Increase and the Technology Transfer shall have
been approved by a majority of the outstanding shares of Nurescell Common Stock
and shall have become effective as provided in Section 1.02 above; and

                  (c) as of the date of satisfaction of the Transfer Condition
in subsection (b) above (the "Satisfaction Date"):

                  (i) no preliminary or permanent injunction or other order
shall have been issued by any federal or state court of competent jurisdiction
in the United States or by any United States federal or state governmental or
regulatory agency, body or authority which prevents consummation of any material
portion of the transactions contemplated by this Agreement and remains in
effect;

                   (ii) no action or proceeding by any governmental or
regulatory agency, body or authority shall have been commenced or threatened
(and remain pending or threatened) against any party to this Agreement or any of
their respective affiliates, officers or directors seeking to prevent or
challenging any material portion of the transactions contemplated by this
Agreement; and

                   (iii) no action or proceeding before any federal or state
court of competent jurisdiction in the United States shall have been commenced
(and remain pending) against any party to this Agreement or any of their
respective affiliates, officers or directors seeking to prevent or challenging
any material portion of the transactions contemplated hereby or seeking material
damages in connection therewith.

         2.03 STATUS OF THE TECHNOLOGY. ATI and ATI Sub are aware that at such
time as the Technology is transferred pursuant to Section 2.01 above, such
transfer will be in "as is" condition and, except as provided in Section 3.04(c)
below, will be made without representation or warranty of any kind, including
warranties as to marketability and fitness for any particular purpose. ATI and
ATI Sub are fully aware of the extent and nature of the Technology, have fully
investigated all matters with respect thereto and are fully aware of all laws
and regulations which relate to Nurescell's transfer thereof, and,
notwithstanding any other provision of this Agreement, hereby assume all risk
thereof and waive any liability of Nurescell and/or Triton with respect thereto.
In light of ATI Sub's security interest in the Collateral, the parties hereto
agree that the transfer of the Technology pursuant to this Agreement constitutes
a transfer of collateral pursuant to Section 9609 of the California Uniform
Commercial Code.

         2.04 FURTHER ACTS.

                  (a) Prior to the Closing Date, Triton shall take any action
necessary to vote all of its Nurescell Common Stock in favor of the approval and
authorization of the Share Increase and the Technology Transfer, including
signing a written consent in the form of the attached Exhibit "E."

                  (b) On the Closing Date, Nurescell shall deliver to ATI Sub
(i) an executed separate assignment document in the form provided by ATI Sub, to
be recorded by ATI Sub with the U.S. Patent and Trademark Office evidencing the
transfer of the Technology to ATI Sub and (ii) all documentation pertaining to
the Technology not previously delivered to ATI or ATI Sub, including, without
limitation, copies of all correspondence to and from examining authorities
regarding the Technology, all patent and prior art searches and all
correspondence with any attorneys involving the preparation or prosecution of
patents relating to the Technology.

<PAGE>

                  (c) After the Closing Date, Triton, Nurescell, ATI and ATI Sub
each agree to promptly perform any acts and execute and deliver any further
documents which may be reasonably requested in order to reflect the transactions
occurring on the Closing Date, including, but not limited to, each party to the
Assignment Agreement and the Mutual Release providing the other parties thereto
with a signed copy of such agreement; provided, however, that each party to such
agreements shall be bound thereby on and after the Closing Date even without
their signature thereon.

                                   ARTICLE III
                  REPRESENTATIONS AND WARRANTIES OF THE PARTIES
                  ---------------------------------------------

         3.01 Representations and Warranties by Nurescell to Triton. As an
inducement to Triton to enter into this Agreement and to consummate the
transactions contemplated herein, as of the Effective Date and the Satisfaction
Date, Nurescell hereby represents and warrants to Triton, and agrees, as
follows:

                  (a) That it is a corporation duly organized, validly existing
and in good standing in the jurisdiction where it was formed and it has the full
power and authority to own, lease and operate its properties and conduct the
business being conducted by it and is duly qualified to transact business and in
good standing in every jurisdiction in which the character of the business
conducted by it makes such qualification necessary.

                  (b) Except as set forth in the attached Schedule 3.01(b), its
execution, delivery and performance of this Agreement and each other document
provided for or referred to herein has been duly authorized and approved by all
requisite corporate action on its part. Neither the execution nor the delivery
of this Agreement and such other documents, nor the consummation of the
transactions contemplated hereby or thereby, nor compliance with or fulfillment
of the terms and provisions of this Agreement or such other documents, will
conflict with or result in a breach of the terms, conditions or provisions of or
constitute a default under (i) its organizational documents, (ii) any promissory
note of which it is the maker or guarantor, (iii) any law or administrative
regulation applicable to it or its properties or (iv) any indenture, agreement,
mortgage, judgment, order, award, decree or other instrument or restriction to
which it is a party or by which it is bound, or give any party with rights under
any such indenture, agreement, mortgage, judgment, order, award, decree or other
instrument or restriction the right to terminate, modify or otherwise change its
rights or obligations under such indenture, agreement, mortgage, judgment,
order, award, decree or other instrument or restriction. Except as set forth in
the attached Schedule 3.01(b), no authorization, approval or consent of, or
notice to or filing with, any person or entity or any governmental department,
commission, bureau or agency or other public body or authority is or will be
required for the execution, delivery or performance of this Agreement by it or
for the consummation by it of the transactions contemplated hereby. It has the
full power and authority to do and perform all acts and things required to be
done by it under this Agreement. All corporate acts and other proceedings
required to be taken by it or on its part to authorize it to carry out this
Agreement and such other agreements and instruments as are contemplated hereby
and the transactions contemplated hereby and thereby have been duly and properly
taken. This Agreement constitutes, and such other agreements and instruments
when duly executed (if required) and delivered by it will constitute, legal,
valid and binding obligations and will be enforceable against it in accordance
with their respective terms.

<PAGE>

                  (c) ATI is the sole owner of the ATI Shares and, except for
(i) the ATI Shares, (ii) ATI Sub's option to acquire shares of Nurescell Common
Stock as set out in the Investment Agreement and (iii) the interests in the
Collateral, neither ATI nor ATI Sub owns or has any right to acquire any
interest in Nurescell.

                  (d) Except for the License Agreement, the Investment
Agreement, the Modification Agreement, the 2001 Restructure Agreement and the
ATI Sub Note (collectively, the "ATI Agreements") and this Agreement, there are
no written or oral agreements currently in effect or pending between Nurescell
and ATI and/or ATI Sub.

                  (e) The attached Exhibit "F" accurately reflects each of
Nurescell's accounts payable, other current liabilities, long-term liabilities
and contingent liabilities and obligations as of the Effective Date.

                  (f) Nurescell does not do business in Nevada and, as shown by
its stock ledger, Nurescell does not have more than 99 shareholders with
addresses in Nevada.

                  (g) All financial information contained in Nurescell' s Form
10-KSB for the fiscal year ended March 31, 2002 and Form 10-QSB for the quarter
ended September 30, 2002 (collectively, the "SEC Filings") is true and correct
in all material respects and there has been no material change in Nurescell's
financial condition from March 31, 2002 or September 30, 2002 to the Effective
Date. To its best knowledge, other than as set forth in the attached Schedule
3.01(g), it is not aware of any material actual or contingent liabilities of
Nurescell except as set forth in the SEC Filings.

                  (h) To the best knowledge of its executive officers, except as
set forth on Exhibit "F" or otherwise described in the SEC Filings, it is not
aware of (i) any pending or threatened claims by or against Nurescell by any
person or entity or (ii) any past occurrences which could reasonably be expected
to result in a claim against Nurescell.

                  (i) It has committed no act or omission which would cause any
person, firm, corporation or other entity to be entitled to any broker's or
finder's fee, commission, or other similar compensation with respect to the
execution and delivery of this Agreement or any related agreement, or with
respect to the consummation of the transactions contemplated herein.

                  (j) No representation or warranty by it herein or in any
document provided by it in connection herewith, and no information disclosed
herein or in any document supplied by it in connection herewith, contains any
untrue statement of a material fact or omits a material fact necessary to make
the statements contained herein or therein not misleading.

<PAGE>

         3.02 REPRESENTATIONS AND WARRANTIES BY TRITON TO NURESCELL, ATI AND ATI
SUB. As an inducement to Nurescell, ATI and ATI Sub to enter into this Agreement
and to consummate the transactions contemplated herein, as of the Effective Date
and the Satisfaction Date, Triton hereby represents and warrants to Nurescell,
ATI and ATI Sub, and agrees, as follows:

                  (a) That it is a limited partnership duly organized, validly
existing and in good standing in the State of Delaware.

                  (b) Its execution, delivery and performance of this Agreement
and each other document provided for or referred to herein has been duly
authorized and approved by all requisite action on its part. Neither the
execution nor the delivery of this Agreement and such other documents, nor the
consummation of the transactions contemplated hereby or thereby, nor compliance
with or fulfillment of the terms and provisions of this Agreement or such other
documents, will conflict with or result in a breach of the terms, conditions or
provisions of or constitute a default under (i) its organizational documents,
(ii) any promissory note of which it is the maker or guarantor, (iii) any law or
administrative regulation applicable to it or its properties or (iv) any
indenture, agreement, mortgage, judgment, order, award, decree or other
instrument or restriction to which it is a party or by which it is bound. No
authorization, approval or consent of, or notice to or filing with, any person
or entity or any governmental department, commission, bureau or agency or other
public body or authority is or will be required for the execution, delivery or
performance of this Agreement by it or for the consummation by it of the
transactions contemplated hereby. It has the full power and authority to do and
perform all acts and things required to be done by it under this Agreement. All
acts and other proceedings required to be taken by it or on its part to
authorize it to carry out this Agreement and such other agreements and
instruments as are contemplated hereby and the transactions contemplated hereby
and thereby have been duly and properly taken. This Agreement constitutes, and
such other agreements and instruments when duly executed (if required) and
delivered by it will constitute, legal, valid and binding obligations and will
be enforceable against it in accordance with their respective terms.

                  (c) It has committed no act or omission which would cause any
person, firm, corporation or other entity to be entitled to any broker's or
finder's fee, commission, or other similar compensation with respect to the
execution and delivery of this Agreement or any related agreement, or with
respect to the consummation of the transactions contemplated herein.

         3.03 REPRESENTATIONS AND WARRANTIES BY ATI AND ATI SUB TO NURESCELL. As
an inducement to Nurescell to enter into this Agreement and to consummate the
transactions contemplated herein, as of the Effective Date and the Satisfaction
Date, ATI and ATI Sub each hereby severally, and not jointly, represent and
warrant to Nurescell, and agree, as follows:

                  (a) That it is a corporation duly organized, validly existing
and in good standing in the jurisdiction where it was formed.

                  (b) Its execution, delivery and performance of this Agreement
and each other document provided for or referred to herein has been duly
authorized and approved by all requisite corporate action on its part. Neither
the execution nor the delivery of this Agreement and such other documents, nor
the consummation of the transactions contemplated hereby or thereby, nor
compliance with or fulfillment of the terms and provisions of this Agreement or
such other documents, will conflict with or result in a breach of the terms,

<PAGE>

conditions or provisions of or constitute a default under (i) its organizational
documents, (ii) any promissory note of which it is the maker or guarantor, (iii)
any law or administrative regulation applicable to it or its properties or (iv)
any indenture, agreement, mortgage, judgment, order, award, decree or other
instrument or restriction to which it is a party or by which it is bound. No
authorization, approval or consent of, or notice to or filing with, any person
or entity or any governmental department, commission, bureau or agency or other
public body or authority is or will be required for the execution, delivery or
performance of this Agreement by it or for the consummation by it of the
transactions contemplated hereby. It has the full power and authority to do and
perform all acts and things required to be done by it under this Agreement. All
corporate acts and other proceedings required to be taken by it or on its part
to authorize it to carry out this Agreement and such other agreements and
instruments as are contemplated hereby and the transactions contemplated hereby
and thereby have been duly and properly taken. This Agreement constitutes, and
such other agreements and instruments when duly executed (if required) and
delivered by it will constitute, legal, valid and binding obligations and will
be enforceable against it in accordance with their respective terms.

                  (c) It has committed no act or omission which would cause any
person, firm, corporation or other entity to be entitled to any broker's or
finder's fee, commission, or other similar compensation with respect to the
execution and delivery of this Agreement or any related agreement, or with
respect to the consummation of the transactions contemplated herein.

         3.04 REPRESENTATIONS AND WARRANTIES BY NURESCELL TO ATI AND ATI SUB. As
an inducement to ATI and ATI Sub to enter into this Agreement and to consummate
the transactions contemplated herein, as of the Effective Date and the
Satisfaction Date, Nurescell hereby represents and warrants to ATI and ATI Sub,
and agrees, as follows:

                  (a) That it is a corporation duly organized, validly existing
and in good standing in the State of Nevada.

                  (b) Except as set forth in the attached Schedule 3.01(b), its
execution, delivery and performance of this Agreement and each other document
provided for or referred to herein has been duly authorized and approved by all
requisite corporate action on its part. Neither the execution nor the delivery
of this Agreement and such other documents, nor the consummation of the
transactions contemplated hereby or thereby, nor compliance with or fulfillment
of the terms and provisions of this Agreement or such other documents, will
conflict with or result in a breach of the terms, conditions or provisions of or
constitute a default under (i) its organizational documents, (ii) any promissory
note of which it is the maker or guarantor, (iii) any law or administrative
regulation applicable to it or its properties or (iv) any indenture, agreement,
mortgage, judgment, order, award, decree or other instrument or restriction to
which it is a party or by which it is bound. Except as set forth in the attached
Schedule 3.01(b), no authorization, approval or consent of, or notice to or
filing with, any person or entity or any governmental department, commission,
bureau or agency or other public body or authority is or will be required for
the execution, delivery or performance of this Agreement by it or for the
consummation by it of the transactions contemplated hereby. It has the full
power and authority to do and perform all acts and things required to be done by
it under this Agreement. All corporate acts and other proceedings required to be
taken by it or on its part to authorize it to carry out this Agreement and such
other agreements and instruments as are contemplated hereby and the transactions
contemplated hereby and thereby have been duly and properly taken. This
Agreement constitutes, and such other agreements and instruments when duly
executed (if required) and delivered by it will constitute, legal, valid and
binding obligations and will be enforceable against it in accordance with their
respective terms.

<PAGE>

                  (c) Nurescell has good title to the Technology, free and clear
of all liens, security interests, claims, rights and encumbrances except those
presently existing in favor of ATI and/or ATI Sub.

                  (d) It has committed no act or omission which could cause any
person, firm, corporation or other entity to be entitled to any broker's or
finder's fee, commission, or other similar compensation with respect to the
execution and delivery of this Agreement or any related agreement, or with
respect to the consummation of the transactions contemplated herein.

                  3.05 REPRESENTATIONS AND WARRANTIES BY ATI AND ATI SUB TO
TRITON. As an inducement to Triton to enter into this Agreement and to
consummate the transactions contemplated herein, as of the Effective Date and
the Satisfaction Date, ATI and ATI Sub each hereby severally, and not jointly,
represent and warrant to Triton, and agree, as follows:

                  (a) That it is a corporation duly organized, validly existing
and in good standing in the jurisdiction where it was formed.

                  (b) Except as set forth in the attached Schedule 3.05(b), its
execution, delivery and performance of this Agreement and each other document
provided for or referred to herein has been duly authorized and approved by all
requisite corporate action on its part. Neither the execution nor the delivery
of this Agreement and such other documents, nor the consummation of the
transactions contemplated hereby or thereby, nor compliance with or fulfillment
of the terms and provisions of this Agreement or such other documents, will
conflict with or result in a breach of the terms, conditions or provisions of or
constitute a default under (i) its organizational documents, (ii) any promissory
note of which it is the maker or guarantor, (iii) any law or administrative
regulation applicable to it or its properties or (iv) any indenture, agreement,
mortgage, judgment, order, award, decree or other instrument or restriction to
which it is a party or by which it is bound. Except as set forth in the attached
Schedule 3.05(b), no authorization, approval or consent of, or notice to or
filing with, any person or entity or any governmental department, commission,
bureau or agency or other public body or authority is or will be required for
the execution, delivery or performance of this Agreement by it or for the
consummation by it of the transactions contemplated hereby. It has the full
power and authority to do and perform all acts and things required to be done by
it under this Agreement. All corporate acts and other proceedings required to be
taken by it or on its part to authorize it to carry out this Agreement and such
other agreements and instruments as are contemplated hereby and the transactions
contemplated hereby and thereby have been duly and properly taken. This
Agreement constitutes, and such other agreements and instruments when duly
executed (if required) and delivered by it will constitute, legal, valid and
binding obligations and will be enforceable against it in accordance with their
respective terms.

<PAGE>

                  (c) ATI is the sole owner of 4,590,000 shares of Nurescell
Common Stock and, except for (i) those shares, (ii) ATI Sub's option to acquire
shares of Nurescell Common Stock as set out in the Investment Agreement and
(iii) the interests in the Collateral, neither ATI nor ATI Sub owns or has any
right to acquire any interest in Nurescell.

                  (d) Except for this Agreement and the ATI Agreements, there
are no written or oral agreements currently in effect or pending between
Nurescell and ATI and/or ATI Sub.

                  (e) It has committed no act or omission which would cause any
person, firm, corporation or other entity to be entitled to any broker's or
finder's fee, commission, or other similar compensation with respect to the
execution and delivery of this Agreement or any related agreement, or with
respect to the consummation of the transactions contemplated herein.

                                   ARTICLE IV
                         OTHER AGREEMENTS OF THE PARTIES
                         -------------------------------

         4.01 AGREEMENTS BY ATI AND ATI SUB. ATI and ATI Sub each agree that,
unless otherwise consented to in writing by Triton, during the period from the
Effective Date until the earlier of (i) the Closing Date or (ii) the date this
Agreement is terminated through no fault of ATI or ATI Sub:

                  (a) They shall not acquire, nor shall they cause or permit any
"affiliate" (as defined in Rule 405 under the Securities Act of 1933; provided
that Nurescell shall not be considered an affiliate) to acquire, any additional
shares of Nurescell or any rights with respect thereto.

                  (b) They shall not take any action, nor shall they cause or
permit any affiliate to take any action, against Nurescell with respect to the
ATI Agreements or otherwise.

                  (c) They shall not transfer any rights with respect to the ATI
Agreements or any shares or other interest in Nurescell.

                  (d) They shall each use their best efforts to perform or
fulfill all conditions and obligations to be performed or fulfilled by them
under this Agreement so that the transactions contemplated hereby shall be
consummated as soon as practicable. They also agree that they shall each use
their best efforts to cooperate with the other parties hereto so as to cause the
Transfer Conditions to occur as soon as practicable.

         4.02 AGREEMENTS BY TRITON. Triton agrees that during the period from
the Effective Date until the earlier of (i) the Closing Date or (ii) the date
this Agreement is terminated through no fault of Triton, it shall (A) use its
best efforts to perform or fulfill all conditions and obligations to be
performed or fulfilled by it under this Agreement so that the transactions
contemplated hereby shall be consummated as soon as practicable, (B) use its
best efforts to cooperate with the other parties hereto so as to cause the
Transfer Conditions to occur as soon as practicable and (C) not take any action
against Nurescell with respect to the 1999 Note, the 2000 Note, the Registration
Agreements, the Securities Purchase Agreement dated as of December 15, 1999, the
Warrant to Purchase Common Stock dated December 15, 1999, the Securities
Purchase Agreement dated as of February 8, 2000, the Warrant to Purchase Common
Stock dated February 8, 2000, the Pledge and Security Agreement dated August 8,
2002, the $26,000 Secured Promissory Note dated August 8, 2002, the $7,650
Unsecured Promissory Note dated August 26, 2002, or otherwise.

<PAGE>

         4.03 AGREEMENTS BY NURESCELL. Nurescell agrees that during the period
from the Effective Date until the earlier of (i) the Closing Date or (ii) the
date this Agreement is terminated through no fault of Nurescell, Nurescell
shall:

                  (a) use its best efforts to perform or fulfill all conditions
and obligations to be performed or fulfilled by it under this Agreement so that
the transactions contemplated hereby shall be consummated as soon as
practicable;

                  (b) use its best efforts to cooperate with the other parties
hereto so as to cause the Transfer Conditions to occur as soon as practicable;

                  (c) not take any action, nor shall it cause or permit any
affiliate over which Nurescell has control to take any action, against ATI or
ATI Sub with respect to the ATI Agreements or otherwise;

                  (d) not transfer any rights with respect to the Technology,
the ATI Agreements or other interest in ATI;

                  (e) reasonably cooperate with ATI and ATI Sub in the filing
and prosecution of any patent application and other similar filings related to
the protection of the Technology; and

                  (f) not establish any liens, security interests, claims,
rights and encumbrances against title to the Technology except in favor of ATI
and/or ATI Sub.

         4.04 Agreement as to Liabilities. Nurescell agrees that on and after
the Closing Date, unless otherwise specified in this Agreement or an Exhibit or
Schedule hereto, neither ATI nor ATI Sub shall be liable for any currently
existing or future liabilities of Nurescell.

                                    ARTICLE V
                       TERMINATION, AMENDMENT AND SURVIVAL
                       -----------------------------------

         5.01 TERMINATION. This Agreement may be terminated and the transactions
contemplated hereby may be abandoned only:

                  (a) by mutual consent of each of the parties; or

                  (b) by one party unilaterally, if (i) there has been a
material breach by another party of any of its representations, warranties or
covenants set forth in this Agreement and such breach has not been cured (or
cure commenced followed by prompt completion) within twenty (20) days after
written notice thereof to such party and (ii) the party seeking termination is
not also in material breach of any of its representations, warranties or
covenants set forth in this Agreement.

<PAGE>

         5.02 TERMINATION REMEDIES. Notwithstanding termination of this
Agreement, in the event that the transactions described herein are not
consummated due to a material breach of this Agreement by a party, the other
parties shall have all rights and remedies at law and in equity available to it
for such breach, including the right to specific performance.

         5.03 AMENDMENT AND WAIVER. No waiver or amendment of any provision of
this Agreement shall be effective unless in writing and signed by the party to
be bound. No delay or omission of any party hereto in exercising any right or
remedy hereunder shall constitute a waiver of such right or remedy, and no
waiver as to any obligation shall operate as a continuing waiver or as a waiver
of any subsequent breach.

         5.04 SURVIVAL OF TERMS. The provisions of this Section, Articles III,
VI and VII and Sections 1.03, 2.03, 2.04(b) and 2.04(c) shall survive the
Effective Date and the Closing Date and continue in full force and effect at all
times thereafter. In addition, the provisions of this Section, Article VII
(except Section 7.02) and Section 5.02 shall survive the termination of this
Agreement and continue in full force and effect at all times thereafter (with
provisions of Article VI also surviving for purposes of Section 5.02).

                                   ARTICLE VI
                                 INDEMNIFICATION
                                 ---------------

         6.01 INDEMNIFICATION. At all times after the Effective Date, upon
demand, each party shall indemnify, defend and hold each other applicable party
and such other party's directors, officers, employees, agents, consultants,
advisors, shareholders and affiliates (collectively, the "Indemnified Persons")
harmless from and against any and all costs and expenses (including reasonable
costs of investigation and attorneys' fees) and other losses, liabilities and
damages resulting from any breach by such party of any representation, warranty
or covenant in this Agreement or any Exhibit, Schedule or other document
provided in connection herewith.

         6.02 INDEMNIFICATION PROCEDURE. No party shall be required to indemnify
any Indemnified Person with respect to any claim under Section 6.01 above unless
the Indemnified Person seeking indemnification (the "Indemnitee") shall notify
the other party (the "Indemnitor") of such claim, shall provide the Indemnitor
with a copy of any relevant documents with respect to such claim, and shall
otherwise make available to the Indemnitor all relevant material information
with respect to such claim; provided, however, that the Indemnitee's failure to
give notice or to provide copies of documents or to furnish relevant information
shall not constitute a defense (in whole or in part) to any claim by the
Indemnitee against the Indemnitor except and only to the extent that such
failure by the Indemnitee shall result in a material prejudice to the
Indemnitor. The Indemnitor, at its sole cost and expense, shall have the right
to defend against any claim brought by a third party, either in its own name or
in the name of the Indemnitee, as may be required, and the Indemnitee, at its
sole cost and expense, shall have the right to participate in such defense. The
Indemnitee shall not settle or compromise any third party claim unless it shall
first obtain the written consent of the Indemnitor (provided such consent is not
unreasonably withheld or delayed) or unless suit shall have been instituted
against the Indemnitee and the Indemnitor shall have failed, after the lapse of
a reasonable time after written notice to it of such suit, to take action to
defend the same or unless the Indemnitor shall have failed to notify the
Indemnitee in writing of its intention to contest the claim within twenty (20)
days of the giving of the above notice from the Indemnitee to the Indemnitor.

<PAGE>

                                   ARTICLE VII
                                  MISCELLANEOUS
                                  -------------

         7.01 COSTS AND EXPENSES. Except as specified in Section 6.01 or 7.11,
all expenses (including attorney's and accountant's fees) in connection with (i)
the preparation and negotiation of this Agreement and the other agreements and
documents referred to herein and (ii) the consummation of the transactions
referred to herein or therein, shall be borne by the party who incurred them.

         7.02 FURTHER ASSURANCES. From time to time after the Effective Date and
the Closing Date, each party agrees to promptly perform any acts and execute and
deliver any further documents which may be reasonably requested by another party
in order to consummate more effectively the transactions contemplated hereby.

         7.03 NOTICES. All notices and other communications required or
permitted to be given under this Agreement shall be in writing and shall be
deemed to have been sufficiently given if personally delivered, telecopied, sent
by overnight courier or deposited in the United States Mail, in a properly
stamped envelope, certified mail, return receipt requested, addressed to the
party to whom it is to be given, at the address set forth below. A notice or
other communication shall be deemed received (i) upon receipt, if personally
delivered, (ii) on the first business day after dispatch, if sent by overnight
courier, (iii) on the first business day after dispatch, if transmitted by
telecopy, and (iv) on the earlier of delivery (as evidenced by the signed return
receipt) or three (3) days after mailing, if sent by certified mail. A party
hereto may change its address by written notice in accordance with this Section.

         (a) If to Nurescell, as specified in (b) or (c) below, as applicable.

         (b) If to Triton, at:

                           220 Executive Center
                           225 North Market Street
                           Wichita, Kansas 67202
                           Telecopy number: (316) 267-0204
                           Attn: John C. Tausche

                  with a copy to:

                           David S. Hamilton, Esq.
                           5699 Kanan Road, #251
                           Agoura Hills, California  91301
                           Telecopy number: (818) 879-5449

<PAGE>

         (c) If to ATI and/or ATI Sub, at:

                           Advanced Technology Industries, Inc.
                           Taubenstrasse 20
                           Berlin, Germany 10117
                           Telecopy number: 011 49 30 201 77899
                           Attn: Hans-Joachim Skrobanek

                           ATI Nuklear AG
                           Taubenstrasse 20
                           Berlin, Germany 10117
                           Telecopy number: 011 49 30 201 77899
                           Attn: J.P. Lempert

                   with copies to:

                           Reboul, MacMurray, Hewitt & Maynard
                           45 Rockefeller Plaza
                           New York, New York 10111
                           Telecopy number: (212) 841-5725
                           Attn: Anthony Norris

                           James Samuelson
                           2030 Main Street, Suite 1300
                           Irvine, California 92614
                           Telecopy number: (949) 260-4799

         7.04 ENTIRE AGREEMENT; REPRESENTATIONS AND WARRANTIES. This Agreement,
together with its Exhibits, Schedules and other documents expressly referred to
herein, contains the entire agreement of the parties with respect to its subject
matter and supersedes all prior negotiations, agreements and understandings,
written or oral, with respect to such subject matter. Other than as set forth in
Article III hereof or otherwise contained herein or in any Exhibit, Schedule or
other document delivered pursuant hereto, the parties make no representations or
warranties of any kind, whether express or implied, in connection with the
transactions contemplated hereby.

         7.05 SEVERABILITY. Should any part of this Agreement for any reason be
declared invalid or unenforceable, such decision shall not affect the validity
or enforceability of any remaining portion, which remaining portion shall remain
in force and effect, and the application of such part to persons or
circumstances other than those as to which it is held invalid or unenforceable,
and each other term, covenant and condition of this Agreement, shall be valid
and be enforced to the fullest extent permitted by law.

         7.06 BINDING EFFECT; BENEFIT. This Agreement and all provisions hereof
shall be binding upon and shall inure only to the benefit of the parties hereto
and their respective successors and permitted assigns; provided, however, that
neither this Agreement nor any of the rights, interests or obligations hereunder
shall be assigned by any party hereto without the prior written consent of the
other parties. Except for Indemnified Persons under Article VI, this Agreement
is not intended to confer upon any person or entity other than the parties
hereto any rights or remedies hereunder.

<PAGE>

         7.07 HEADINGS. The descriptive headings of the Articles and Sections of
this Agreement are inserted for convenience only, do not constitute a part of
this Agreement and shall not affect in any way the meaning or interpretation of
this Agreement.

         7.08 COUNTERPARTS. This Agreement may be executed in counterparts, each
of which shall be deemed to be an original, and all of which together shall be
deemed to be one and the same instrument.

         7.09 APPLICABLE LAW. This Agreement shall be governed by, and construed
in accordance with, the laws of the State of California, without regard to the
conflicts of laws rules thereof. The parties agree that the exclusive venue for
resolution of any case or controversy arising out of or in connection with this
Agreement shall be Los Angeles County, California.

         7.10 INTERPRETATION. Each party intends that this Agreement be deemed
and construed to have been jointly prepared by the parties. As a result, the
parties agree that any uncertainty or ambiguity existing herein shall not be
interpreted against any of them. The parties also intend that the rights and
remedies hereunder be cumulative, so that exercise of any one or more of such
rights or remedies shall not preclude the later or concurrent exercise of any
other rights or remedies.

         7.11 ATTORNEYS' FEES. If any party to this Agreement shall bring any
action for any relief against any other party hereto arising out of or in
connection with this Agreement or any Exhibit, Schedule or other document in
connection herewith, in addition to all other remedies to which the prevailing
party may be entitled, the losing party shall be required to pay to the
prevailing party a reasonable sum for attorney's fees and costs incurred in
bringing such action and/or enforcing any judgment granted therein, all of which
shall be deemed to have accrued upon the commencement of such action and shall
be paid whether or not such action is prosecuted to judgment. Any judgment or
order entered in such action shall contain a specific provision providing for
the recovery of attorney's fees and costs incurred in enforcing such judgment.
For the purposes of this Section, attorney's fees shall include, without
limitation, fees incurred with respect to the following: (i) post-judgment
motions, (ii) contempt proceedings, (iii) garnishment, levy and debtor and third
party examinations, (iv) discovery and (v) bankruptcy litigation.
<PAGE>

         IN WITNESS WHEREOF, this Agreement has been duly executed and delivered
by the duly authorized officers of the parties hereto on the Effective Date.

                                          NURESCELL INC.

                                          By:
                                              ----------------------------------
                                              President
                                          By:
                                              ----------------------------------
                                              Secretary

                                          TRITON PRIVATE EQUITIES FUND, L.P.
                                          By: Triton Capital Management, L.L.C.,
                                              General Partner

                                            By: /s/ John C. Tausche
                                                --------------------------------
                                                John C. Tausche, Member

                                          ADVANCED TECHNOLOGY INDUSTRIES,  INC.

                                          By:
                                              ----------------------------------
                                              President
                                          By:
                                              ----------------------------------
                                              Secretary

                                          ATI NUKLEAR AG

                                          By:
                                              ----------------------------------
                                              President
                                          By:
                                              ----------------------------------
                                              Secretary

         The foregoing is hereby consented to as of the Effective Date

                                          LTDNETWORK, INC.

                                          By:
                                              ----------------------------------
                                          Title:

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00048-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00048-of-00352.parquet"}]]